EdiTy Therapeutics
Richard ‘Rick’ Kendall has more than 30 years of experience in biotechnology and the biopharmaceutical industry including executive positions at Kite Pharma and Amgen. Most recently he served as CEO at ImmPACT-Bio USA Inc.
This person is not in the org chart
This person is not in any offices
EdiTy Therapeutics
EdiTy Therapeutics is a biotechnology company that develops a gene-editing technology designed for in-vivo gene-editing of target cells.